Heart Failure Hospitalization

Efficacy and Safety of Sacubitril/Valsartan in the Management of Heart Failure with Reduced Ejection on Fraction on and Chronic Kidney Disease: A Systema c Review and Meta-Analysis

by Prateek Chopra | May 23, 2026 | Cardiology Conferences | ESC-HF 2026 Patients with heart failure with reduced ejection fraction (HFrEF) and advanced chronic kidney disease (CKD) have limited therapeutic options and poor prognosis. Although sacubitril/valsartan has improved outcomes in HFrEF, major trials excluded patients with CKD stage 4 or higher, leaving uncertainty regarding its efficacy and safety in this […]

Efficacy and Safety of Sacubitril/Valsartan in the Management of Heart Failure with Reduced Ejection on Fraction on and Chronic Kidney Disease: A Systema c Review and Meta-Analysis Read Post »

Leave a Comment / ESC-HF Day 2 / bluetree.healthcare@gmail.com / July 30, 2026 / Cardiorenal Syndrome, Chronic Kidney Disease (CKD), Heart Failure Hospitalization, Heart Failure with Reduced Ejection Fraction (HFrEF), Sacubitril/Valsartan (ARNI)

Effect of Different Treatment Durations of Sodium–Glucose Cotransporter2 Inhibitor on Cardiovascular Outcomes in Patients with Type 2 Diabetes:A Target Trial Emulation Study

by Prateek Chopra | July 4, 2026 | Diabetes Conferences | ADA 2026 Clinical Background Methods Study Population Key Findings Clinical Implications In this large nationwide analysis, longer SGLT2i treatment duration was associated with progressively greater reductions in major adverse cardiovascular events and hospitalization for heart failure, supporting sustained therapy to optimize cardiovascular outcomes in patients with type 2 diabetes.